Summary of Invention This invention represents a novel approach to treat H3K27M gliomas, which are highly lethal and predominantly occur in children as midline brain tumors or spinal tumors. This approach uses T-cells engineered to express a chimeric antigen receptor (CAR) that targets the GD2 ganglioside, a cell surface disialoganglioside shown by the inventors to be overexpressed on midline gliomas. The treatment is designed to improve survival of patients with H3K27M gliomas while minimizing on-target, off-tumor activity of the CAR T-cells. International Publication Number WO 2019/014456 A1 (.pdf) International Application Filing Date 07.12.18 Inventors Crystal Mackall, MD Michelle Monje-Deisseroth, MD, PhD Christopher Mount Robbie Majzner, MD Institution Stanford Medicine Category (Neo)antigens CAR/TCR T-cells/Adoptive Cell Therapy